INDIANAPOLIS — Indiana University Research and Technology Corp., which protects intellectual property developed in the Indiana University campus system, has licensed technology that creates human blood vessels to Cellular Dynamics International, a Fujifilm company based in Madison, Wisconsin.
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced an agreement with Roche to supply CDI’s induced pluripotent stem cell (iPSC)-derived iCell products to contribute to the identification of novel drug candidates at the early stages of drug discovery.
Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced the launch of the world’s largest publicly available stem cell bank, the California Institute for Regenerative Medicine (CIRM) hPSC Repository, and the availability of the first 300 induced pluripotent stem cell (iPSC) lines in September. These high quality, disease-specific iPSC resources are now accessible to academic and industry researchers for disease modeling, target discovery and drug discovery.
MADISON, WIS., August 20, 2015 — Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, today announced an exclusive agreement with SeouLin Bioscience Co., Ltd., for the distribution of CDI’s products in the Republic of Korea.
MADISON, WIS., August 13, 2015 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company, will host the annual iForum™ 2015 Meeting: US on September 14-16 in Chicago, IL. With the rapidly growing interest in and use of iPSCs over recent years in drug discovery and cell therapy applications, iForum 2015 Meetings represent a natural evolution of the former CDI User Group Meetings. The iForum 2015 Meeting: Europe is slated to be held in Hamburg, Germany, on October 19.
Cellular Dynamics International, Inc. (CDI) announced that its MyCell® Disease & Diversity Products received the 2015 Gold Edison Award in the Science/Medical/Dental Research and Education category at a gala in New York City on April 23, 2015.
OKYO and MADISON, Wis., March 30, 2015 /PRNewswire/ — FUJIFILM Holdings Corporation (President: Shigehiro Nakajima,) (TSE: 4901) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay,) (NASDAQ: ICEL) (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.
MADISON, Wis., Feb. 11, 2015 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL) today announced that its iCell® Hepatocytes, or human liver cells manufactured from induced pluripotent stem cells (iPSCs), have been used as a malaria-in-a-dish model to test anti-malarial drug candidates. Sangeeta N. Bhatia, M.D., Ph.D., of t…
Cutting-edge Study Uses iPSC-derived Cells to Coat Blood Vessels in Kidney Scaffolds MADISON, Wis., Nov. 18, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL) today announced the publication1 of a study in the American Journal of Transplantation describing a key first step in ultimately rebuilding and eventually transplanting organs: recreating a portion of the…
MADISON, Wis., Oct. 27, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL), today announced that the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded the company a $1.2 million contract to manufacture clinically compatible induced pluripotent stem cells (iPSCs) and iPSC-derived human retinal pigment epithelial (RPE) cells. These…